Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

By LabMedica International staff writers
Posted on 25 Aug 2025

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. More...

Each blood cell passing through a radiation field absorbs small amounts of energy that, cumulatively, can weaken the immune system or trigger hematologic toxicity. A new model now offers a way to measure this exposure and improve the safety of cancer treatment.

Researchers at the University of Navarra (Pamplona, Spain) have developed the FLIP-HEDOS method, the first tool to quantify radiation absorbed by blood during therapy. By combining patient anatomy, blood circulation data, and radiotherapy plans, it simulates when and how much blood is irradiated. This approach treats blood as an “organ at risk” and integrates insights from physics, oncology, and engineering to guide personalized radiotherapy planning.

The researchers conducted a study along with clinicians to validate the framework in a real clinical setting. The results showed that factors such as tumor proximity to major blood vessels, the type of radiation applied, and variations in cardiac output significantly shaped blood irradiation. Findings emphasize that even low doses can damage lymphocytes, impairing immune responses during cancer treatment.

FLIP-HEDOS has gained recognition at leading international forums, including the European Society for Radiotherapy and Oncology (ESTRO) in Austria (May 2025), the Radiation Research Society Conference in the U.S. (September 2024), and the Spanish Society of Medical Physics (May 2025). Portions of the work have also been published in journals such as Radiation Physics and Chemistry, Physics in Medicine & Biology, and Clinical Cancer Research. These achievements highlight the tool’s credibility and its potential role in advancing radiation oncology.

Beyond radiotherapy planning, the method could be applied to simulate drug or radiopharmaceutical distribution and to evaluate strategies for radioprotection. Modeling cumulative exposure creates opportunities to optimize treatment schedules and beam directions to reduce blood damage. Researchers see it as a paradigm shift toward protecting the immune system and enhancing patients’ quality of life in precision oncology.

“Thinking of blood as a dynamic organ to be protected represents a paradigm shift in modern radiotherapy,” said Professor Javier Burguete, Professor of Medical Physics and Biophysics at the University of Navarra and director of the thesis. “This research not only responds to a scientific need, but also a clinical imperative: to offer safer treatments without compromising oncological efficacy.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.